GCO Financials

Income Statement
MetricQ2 2027Q1 2027Q4 2026Q4 2026Q3 2026
Revenue
529.9M
+8.8%
487.0M
-39.1%
799.9M
+0.0%
799.9M
+29.8%
616.2M
Cost of Revenue
257.7M
-0.1%
258.1M
-40.4%
432.8M
+0.0%
432.8M
+32.1%
327.6M
Gross Profit
272.1M
+18.9%
228.9M
-37.6%
367.1M
+0.0%
367.1M
+27.2%
288.6M
Operating Expenses
268.5M
+9.9%
244.3M
-22.6%
315.8M
+0.0%
315.8M
+12.8%
280.1M
R&D
0
0
0
0
0
SG&A
259.6M
+2.0%
254.4M
-18.6%
312.4M
+0.0%
312.4M
+13.3%
275.7M
Operating Income
3.6M
+123.5%
-15377000
-130.0%
51.3M
+0.0%
51.3M
+498.4%
8.6M
EBITDA
12.6M
+202.6%
-12237000
-118.1%
67.7M
+0.0%
67.7M
+157.9%
26.3M
Net Income
3.5M
+123.5%
-14814000
-131.1%
47.6M
+0.0%
47.6M
+788.9%
5.4M
EPS (Basic)
$0.33
+123.2%
$-1.42
-130.9%
$4.60
+0.0%
$4.60
+784.6%
$0.52
EPS (Diluted)
$0.32
+122.5%
$-1.42
-132.9%
$4.32
+0.0%
$4.32
+764.0%
$0.50
Shares (Diluted)
10.9M
+4.7%
10.4M
-5.5%
11.0M
+0.0%
11.0M
+3.4%
10.7M
Genes (GCO) โ€” Financials